Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
Compugen (NASDAQ: CGEN) will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 from 8:45–9:25 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Compugen (NASDAQ: CGEN) will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 from 8:45–9:25 AM ET. A live webcast and a replay will be available on the company’s Investor Relations website at www.cgen.com.
Details
News Market Reaction – CGEN
On Apr 9, the day this news came out, CGEN closed 8.30% above the previous close.
Data tracked by StockTitan Argus for the Apr 9 session.
Key Figures
- Conference date
- April 13, 2026
- Needham Virtual Healthcare Conference presentation date
- Presentation time
- 8:45–9:25 AM ET
- Scheduled window for Compugen’s conference presentation
Historical Context
-
Strong 2025 earnings, cash runway into 2029, CEO transition update.
-
Announcement of management participation in two healthcare investor conferences.
-
Scheduling of Q4 and full-year 2025 results release and conference call.
-
Appointment of Dr. Michele Holcomb as independent director to strengthen board.
-
Non-dilutive monetization of rilvegostomig royalties with AstraZeneca for cash.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLON,
A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (Unigen™) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The TIGIT component of rilvegostomig is derived from COM902. In Phase 1 development Compugen has COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody and GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Company contact:
Investor relations
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-25th-annual-needham-virtual-healthcare-conference-302738030.html
SOURCE Compugen Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.